General
Preferred name
PERAMIVIR
Synonyms
BCX-1812 ()
RWJ-270201 ()
S-021812 ()
RWJ 270201 trihydrate ()
BCX 1812 trihydrate ()
RWJ270201 ()
BCX 1812 ()
BCX1812 ()
RWJ 270201 ()
PERAMIVIR ANHYDROUS ()
Peramivir (trihydrate) ()
Peramivir Trihydrate ()
Rapivab ()
Rapiacta ()
Peramivir trihydrate ()
Peramivir hydrate ()
Alpivab ()
RWJ-270201-162 ANHYDROUS ()
P&D ID
PD016191
CAS
229614-56-6
330600-85-6
1041434-82-5
Tags
available
drug
Approved by
FDA
EMA
First approval
2014
Drug indication
influenza
viral disease
Influenza virus infection
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PRICE 85
MOA Peramivir is an inhibitor of influenza neuraminidase, preventing new virus particles from leaving infected cells.
INDICATION Indicated for the treatment of acute uncomplicated influenza in patients 18 years and older who have been symptomatic for no more than two days.[label]
PRICE 77
DESCRIPTION Peramivir Trihydrate is a trihydrate of the anti-infection agent peramivir (RWJ-270201,BCX-1812) which is a transition-state analogue and a potent, specific influenza viral neuraminidase inhibitor with an IC50 of median 0.09 nM. (BOC Sciences Bioactive Compounds)
DESCRIPTION Peramivir Trihydrate (RWJ-270201) is a neuraminidase inhibitor (IC50: 0.09 nM) which prevents normal processing of virus particles such that virus particles are not released from infected cells. Peramivir Trihydrate is a cyclopentane derivative with activity against influenza A and B viruses. (TargetMol Bioactive Compound Library)
DESCRIPTION Peramivir (BCX1812) is a highly selective influenza A and B neuraminidase inhibitor with antiviral activity and anti-cytokine effects, which can be used in the study of novel coronavirus and influenza virus infections. (TargetMol Bioactive Compound Library)
Cell lines
0
Organisms
3
Compound Sets
19
AdooQ Bioactive Compound Library
A11124
BOC Sciences Bioactive Compounds
peramivir-trihydrate-cas-1041434-82-5-item-84-452647
Cayman Chemical Bioactives
23765
ChEMBL Approved Drugs
CHEMBL3989402
CHEMBL139367
ChEMBL Drugs
CHEMBL3989402
CHEMBL139367
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB06614
DrugBank Approved Drugs
DB06614
DrugCentral
4823
DrugCentral Approved Drugs
4823
DrugMAP
DMNXY5K
DrugMAP Approved Drugs
DMNXY5K
EU-OPENSCREEN Bioactive Compound Library
EOS100843
MedChem Express Bioactive Compound Library
HY-17015
HY-17015A
NCATS Inxight Approved Drugs
9ZS94HQO3B
Pandemic Response Box
ReFrame library
TargetMol Bioactive Compound Library
T2522
T21339
External IDs
52
Properties
(calculated by RDKit )
Molecular Weight
328.21
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
6
Rotatable Bonds
7
Ring Count
1
Aromatic Ring Count
0
cLogP
-0.14
TPSA
148.53
Fraction CSP3
0.8
Chiral centers
5.0
Largest ring
5.0
QED
0.28
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Influenza Virus
influenza viral neuraminidase
Antiviral
ERK
IKK
JNK
p38 MAPK
STAT
Pathway
Anti-infection
JAK/STAT Signaling
MAPK/ERK Pathway
NF-κB
Stem Cell/Wnt
Microbiology/virology
Immunology/Inflammation
MOA
Influenza Virus inhibitor
neuraminidase inhibitor
Indication
influenza A virus infection
Solubility
5%TFA: 3 mg/mL (7.84 mM)<br/>DMSO: 0.2 mg/mL (0.52 mM)<br/>Water: Insoluble
Source data